Authored by Karl Simpson
Dr. David Roth was appointed to Infinity Pharmaceuticals Inc. in 2013 as Senior Vice President of Clinical Development and Medical Affairs, now he will fulfil the role of Chief Medical Officer after being promoted to the position. He will succeed Pedro Santabarbara who was previously Chief Medical Officer . Dr. Roth joined Infinity Pharmaceuticals after a lengthy tenure with Pfizer and Wyeth, culminating in the role of VP of Pfizer’s oncology business unit. He brings to the role extensive experience in solid tumor oncology and haematology drug development, having previously been involved in bring therapies to patients with chronic myelogenous leukemia and haemophilia A and B.
He will report to the President of Research and Development, Dr. Julian Adams, who said “David is the ideals person to lead Infinity through the next stage of clinical development as we focus more intensely on developing IPI-145, our PI3K-delta,gamma inhibitor for the treatment of haematological malignancies”.
Dr. David Roth received a B.S from Massachusetts Institute of Technology and an M.D. Harvard-M.I.T Division of Health and Technology.
Liftstream is an executive search and interim management recruitment company working exclusively within the global life science sector. Liftstream is proud to support rare disease day 2014.